Is soluble CD40 ligand a mediator of angiogenesis in patients with coronary artery disease?

Thrombosis Research

Volumn 122, Issue 3, 2008, Pages 307-313

  Lim, Hoong Sern ^a   Tayebjee, Muzahir H ^a   Tan, Kiat T ^a   Patel, Jeetesh V ^a   MacFadyen, Robert J ^a   Lip, Gregory Y H ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

Angiogenesis; Angiopoietin; Atherosclerosis; Soluble CD40 ligand; Vascular endothelial growth factor

Indexed keywords

ANGIOTENSIN I; ANGIOTENSIN II; CD40 LIGAND; HIGH DENSITY LIPOPROTEIN; VASCULOTROPIN;

ADULT; ANGIOCARDIOGRAPHY; ANGIOGENESIS; ARTICLE; ATHEROMA; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART CATHETERIZATION; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REVASCULARIZATION; SINGLE BLIND PROCEDURE; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ANGIOPOIETIN-1; ANGIOPOIETIN-2; BIOLOGICAL MARKERS; CD40 LIGAND; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; SEVERITY OF ILLNESS INDEX; SOLUBILITY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 45849100179     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2007.10.013     Document Type: Article

References (35)

1. Papapetropoulos A., Garcia-Cardena G., Dengler T.J., Maisonpierre P.C., Yancopoulos G.D., and Sessa W.C. Direct actions of angiopoietin-1 on human endothelium: evidence for network stabilisation, cell survival and interaction with other angiogenic growth factors. Lab Invest 79 (1999) 213-223
2. Maisonpierre P.C., Suri C., Jones P.F., Bartunkova S., Wiegand S.J., Radziewski C., et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277 (1997) 55-60
3. Lobov I.B., Brooks P.C., and Lang R.A. Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci USA 99 (2002) 11205-11210
4. Moulton K.S. Plaque angiogenesis and atherosclerosis. Curr Atheroscl Rep 3 (2001) 225-233
5. Shah P.K. Mechanisms of plaque vulnerability and rupture. J Am Coll Cardiol 41 (2003) 15s-22s
6. Schonbeck U., and Libby P. CD40 signaling and plaque instability. Circ Res 89 (2001) 1092-1103
7. Graf D., Muller S., Korthauer U., van Kooten C., Weise C., and Kroczek R.A. A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activation. Eur J Immunol 25 (1995) 1749-1754
8. Reinders M.E., Sho M., Robertson S.W., Geehan C.S., and Briscoe D.M. Proangiogenic function of CD40 ligand-CD40 interactions. J Immunol 171 (2003) 1534-1541
9. FMelter M., Reinders M.E., Sho M., Pal S., Geehan C., Denton M.D., et al. Ligation of CD40 induces the expression of vascular endothelial growth factor by endothelial cells and monocytes and promotes angiogenesis in vivo. Blood 96 (2000) 3801-3808
10. Aukrust P., Muller F., Ueland T., Berget T., Aaser E., Brunsvig A., et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina: possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 100 (1999) 614-620
11. Lee K.W., Lip G.Y.H., and Blann A.D. Plasma angiopoietin-1, angiopoietin-2, angiopoietin receptor Tie2, and vascular endothelial growth factor levels in acute coronary syndromes. Circulation 110 16 (2004) 2355-2360
12. Hamsten A., Walldius G., Szamosi A., Dahlen G., and de Faire U. Relationship of angiographically defined coronary artery disease to serum lipoproteins and apolipoproteins in young survivors of myocardial infarction. Circulation 73 (1986) 1097-1110
13. Austen W.G., Edwards J.E., Frye R.L., Gensini G.G., Gott V.L., Griffith L.S., et al. A reporting system on patients evaluated for coronary artery disease: report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association. Circulation 51 (1975) 5-40
14. Werner G., Ferrari M., Heinke S., Kuethe F., Surber R., et al. Angiographic assessment of collateral connections in comparison with invasively determined collateral function in chronic coronary occlusions. Circulation 107 (2003) 1972-1977
15. Caine G.J., Blann A.D., Stonelake P.S., Ryan P., and Lip G.Y. Plasma angiopoietin-1, angiopoietin-2 and Tie2 in breast and prostate cancer: a comparison with VEGF and Flt-1. Eur J Clin Invest 33 (2003) 883-890
16. Blann A.D., Belgore F.M., McCollum C.N., Silverman S., Lip P.L., and Lip G.Y. Vascular endothelial growth factor and its receptor, Flt-1, in the plasma of patients with coronary or peripheral atherosclerosis, or Type II diabetes. Clin Sci 102 (2002) 187-194
17. Felmeden D.C., Spencer C.G., Belgore F.M., Blann A.D., Beevers D.G., and Lip G.Y. Endothelial damage and angiogenesis in hypertensive patients: relationship to cardiovascular risk factors and risk factor management. Am J Hypertens 16 (2003) 11-20
18. Lim H.S., Blann A.D., and Lip G.Y.H. Soluble CD40 ligand, soluble P-selectin, interleukin-6 and tissue factor in diabetes mellitus: relationship to cardiovascular disease and risk factor intervention. Circulation 109 (2004) 2524-2528
19. Lim H.S., Lip G.Y., and Blann A.D. Angiopoietin-1 and angiopoietin-2 in diabetes mellitus: relationship to VEGF, glycaemic control, endothelial damage/dysfunction and atherosclerosis. Atherosclerosis 180 1 (2005) 113-118
20. Chong A.Y., Freestone B., Blann A.D., and Lip G.Y. Plasma angiopoietin-1, angiopoietin-2 and angiopoietin receptor, Tie2 in congestive heart failure. J Am Coll Cardiol 43 (2004) 423-428
21. Patel J.V., Lim H.S., Nadar S., Tayebjee M., Hughes E.A., and Lip G.Y. Abnormal soluble CD40 ligand and C-reactive protein concentrations in hypertension: relationship to indices of angiogenesis. J Hypertens 24 1 (2006) 117-121
22. Lim H.S., Lip G.Y., and Blann A.D. Angiopoietin-1 and angiopoietin-2 in diabetes mellitus: relationship to VEGF, glycaemic control, endothelial damage/dysfunction and atherosclerosis. Atherosclerosis 180 (2005) 113-118
23. Doyle B., and Caplice N. Plaque neovascularisation and antiangiogenic therapy for atherosclerosis. J Am Coll Cardiol 49 (2007) 2073-2080
24. Flaxenburg J.A., Melter M., Lapchak P.H., Briscoe D.M., and Pal S. The CD40-induced signaling pathway in endothelial cells resulting in the overexpression of vascular endothelial growth factor involves Ras and phosphatidylinositol 3-kinase. J Immunol 172 12 (Jun 15 2004) 7503-7509
25. Danese S., Scaldaferri F., Vetrano S., Stefanelli T., Graziani C., Repici A., et al. Critical role of the CD40-CD40 ligand pathway in regulating mucosal inflammation-driven angiogenesis in inflammatory bowel disease. Gut 56 9 (Sep 2007) 1248-1256
26. Ottaiano A., Pisano C., De Chiara A., Ascierto P.A., Botti G., Barletta E., et al. CD40 activation as potential tool in malignant neoplasms. Tumori 88 5 (Sep-Oct 2002) 361-366
27. Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol 280 (2001) C1358-C1366
28. Kim I., Kim J.H., Ryu Y.S., Liu M., and Koh G.Y. Tumor necrosis factor alpha up-regulates angiopoietin-2 in human umbilical vein endothelial cells. Biochem Biophys Res Commun 269 (2000) 361-365
29. Oh H., Takagi H., Suzuma K., Otani A., Matsumura M., and Honda Y. Hypoxia and vascular endothelial growth factor selectively up-regulate angiopoietin-2 in bovine microvascular endothelial cells. J Biol Chem 274 (1999) 15732-15739
30. Mandriota S.J., Pyke C., Di Sanza C., Quinodoz P., Pittet B., and Pepper M.S. Hypoxia-inducible angiopoietin-2 expression is mimicked by iodonium compounds and occurs in the rat brain and skin in response to systemic hypoxia and tissue ischaemia. Am J Pathol 156 (2000) 2077-2089
31. Moulton K.S., Vakili K., Zurakowski D., Soliman M., Butterfield C., Sylvin E., et al. Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis. Proc Natl Acad Sci USA 100 (2003) 4736-4741
32. Rondina M.T., Lappe J.M., Carlquist J.F., Muhlestein J.B., Kolek M.J., et al. Soluble CD40 ligand as a predictor of coronary artery disease and long-term clinical outcomes in stable patients undergoing coronary angiography. Cardiology 109 (2007) 196-201
33. Schonbeck U., Varo N., Libby P., Buring J., and Ridker P.M. Soluble CD40L and cardiovascular risk in women. Circulation 104 (2001) 2266-2268
34. Topol E.J., and Nissen S.E. Our preoccupation with coronary luminology: the dissociation between clinical and angiographic findings in ischaemic heart disease. Circulation 92 (1995) 2333-2342
35. Giurgea A.G., Margeta C., Maca T., Rezaie-Majd A., Bucek R.A., Manavi M., et al. Simvastatin reduces serum level of vascular endothelial growth factor in hypercholesterolemic patients. J Cardiovasc Pharmacol 47 1 (2006) 30-36